Psoriasis (PsO) is an immune-mediated chronic disease that can affect both the skin and joints. In the Leonardi et al19 open label extension study, etanercept was generally well tolerated. Leonardi CL, Powers JL, Matheson RT, et al. In clinical trials, etanercept administered at a dose of 25 mg subcutaneously twice weekly demonstrated statistically significant Psoriasis Area and Severity Index (PASI) 75 results (defined as a 75 improvement from baseline) of 30 34 at 12 weeks and 44 56 at 24 weeks (Gottlieb et al 2003; Leonardi et al 2003). PubMed; Leonardi CL, Powers JL, Matheson RT, et al. Patients aged at least 18 years, with plaque psoriasis involving 10 or more of body surface area; 148 were screened and 112 were randomly assigned to treatment groups and received study drug.
Leonardi Cl, Powers Jl, Matheson RT, et al; for the Etanercept Psoriasis Study Group. Etanercept as Monotherapy in Patients with Psoriasis. November 20, 2003; Leonardi C.L., Powers J.L., Matheson R.T., et al. Adverse Events Occurring in at Least 5 Percent of Patients in Any Treatment Group. Adverse Events during the Placebo-Controlled Phase (Weeks 0 to 20) and through the End of the Study (Weeks 0 to 36). Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events: A Meta-analysis of Randomized Controlled Trials. Gottlieb AB, Matheson RT, Lowe N, et al.
Adalimumab, etanercept, and infliximab are tumor necrosis factor (TNF) inhibitors that are currently approved by the U. Leonardi CL, Powers JL, Matheson RT, et al; for Etanercept Psoriasis Study Group. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. C.L., Powers, J.L., Matheson, R.T. et al, Etanercept Psoriasis Study Group. Leonardi CL, Powers JL, Matheson RT, et al. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
Efficacy For Plaque Psoriasis
The currently available biological therapies for psoriasis are etanercept, infliximab, adalimumab, and ustekinumab; each of these therapies displays differential properties based on their unique mechanisms of action, which target either tumor necrosis factor or interleukin (IL)-12/23 cytokines, and each biologic has accumulated significant controlled clinical trial and long-term use data to support a positive benefit/risk profile in psoriasis. J.L. Powers, R.T. Matheson, et al., Etanercept Psoriasis Study Group. Leonardi CL, Powers JL, Matheson RT, et al; Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. This study aimed to evaluate the safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept. For scalp lesion, adalimumab showed similar efficacy to etanercept nonresponders.